Recent advances in the HER2 targeted therapy of gastric cancer

Table 1 Clinical trials of HER2-targeted therapy in gastric cancer (after ToGA study)

Trial	Study design	No. of patients	HER2 status	Regimen duration of treatment	Response rate	Prognosis
LOGiC	Phase III/1st Randomized Double Blind	545	HER2 amplification	Lapatinib + XELOX XELOX No description of duration		non-significant prolongation
TyTAN	Phase III/2nd Parallel group Randomized	1923	HER2 amplification	Lapatinib +Paclitaxel Paclitaxel 24 mo	27% vs 9%	OS: 11.0 mo vs 8.9 mo PFS: 5.4 mo vs 4.4 mo
HERBIS-1	Phase II/1st Non-Randomized	56	IHC 3+ IHC 2+ FISH +	S-1/cisplatin + trastuzumab No description of duration	68%	OS: 16.0 mo PFS: 7.8 mo
PF299804	Phase II/2nd Non-Randomized	28 (estimated)	IHC 3+ IHC 2+ FISH +	PF299804 Cycles of 28 d	7.40%	Ongoing
HIROISE (NCT01450646)	Phase III/1st Randomized	400 (estimated)		Trastuzumab + cisplatin  + capecitabine 33 wk		Ongoing
NCT01472029	Phase II/1st Non-Randomized	53		5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab No description of duration		Ongoing
NCT01130337	Phase II/preoperative Non-Randomized	36		Trastuzumab + XELOX 12 mo		Ongoing
NCT01522768	Phase II/advanced Non-Randomized	40	IHC 3+ IHC 2+ FISH +	Afatinib + trastuzumab 24 mo		Ongoing
NCT01402401	Phase II/2nd Non-Randomized	21	IHC 3+ IHC 2+ FISH +	AUY922 + trastuzumab Every 6 wk		Ongoing
NCT01641939	Phase II/III/1st Randomized	412 (estimated)	IHC 3+ IHC 2+ FISH +	Trastuzumab emtansine Taxane 12 wk		Ongoing

HER2: Human epidermal growth factor receptor; OS: Overall survival; PFS: Progression-free survival; IHC: Immunohistochemistry; FISH: Fluorescence in situ hybridization.